ZURICH, Dec 14 (Reuters) - Swiss pharmaceutical group Novartis AG (NOVN.VX: Quote, Profile , Research) on Thursday said the U.S. regulatory review period for blood pressure drug Tekturna, developed with biotech firm Speedel (SPPN.S: Quote, Profile , Research), has been extended by up to three months.
